
GRAIL Inc (GRAL) Stock Forecast & Price Target
GRAIL Inc (GRAL) Analyst Ratings
Bulls say
GRAIL is a leader in the multi-cancer early detection (MCED) market and has the potential to greatly reduce cancer mortality through its Galleri test. With its partnership with Epic and a growing sales force, GRAIL is establishing the infrastructure needed for widespread adoption. While the recent Q1 earnings beat was positive, investors will be keeping a close eye on the upcoming release of ASCO data and FDA approval for potential catalysts. Given the potential upside and the significant risks, this suggests a neutral position on the stock.
Bears say
GRAIL is facing a lack of stability and guidance clarity, with uncertainties in digital health partner uptake, sales force ramp, and the potential impact of the full NHS dataset at ASCO. While Q1 sales beat expectations, there is still a risk of FDA disapproval or Medicare non-reimbursement. However, with the stock trading at a low multiple and significant potential for positive catalysts, a Buy rating is justified with a 75% chance of FDA approval and 50% chance of Medicare coverage in the near future.
This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.
GRAIL Inc (GRAL) Analyst Forecast & Price Prediction
Start investing in GRAIL Inc (GRAL)
Order type
Buy in
Order amount
Est. shares
0 shares